Drug, bio-affecting and body treating compositions inventions 03/07

20070072790 - Antitumor agents: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070072791 - Glycogen synthase kinase-3 inhibitors: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit... Agent: Martin D. Moynihan Prtsi, Inc.

20070072793 - Histone hyperacetylating agents for promoting wound healing and preventing scar formation: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth... Agent: Fish & Richardson PC

20070072792 - Macrocyclic lactams and pharmaceutical use thereof: wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use... Agent: Novartis Corporate Intellectual Property

20070072799 - Acid-labile subunit (als) of insulin-like growth factor binding protein complex: e

20070072803 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Cozen O'connor, P.C.

20070072804 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Cozen O'connor, P.C.

20070072800 - Conjugates for cancer therapy and diagnosis: The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as... Agent: Winston & Strawn LLP Patent Department

20070072797 - Epitopes: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Davis Wright Tremaine, LLP

20070072798 - Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same: This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in human proteolytical system such as serine and cysteine proteases and their inhibitors and pharmaceutical agents and other therapies affecting these. This invention discloses methods for the treatment and prevention of cardiovascular diseases such... Agent: Birch Stewart Kolasch & Birch

20070072801 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070072794 - Novel genes and proteins encoded thereby: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom,... Agent: Olson & Hierl, Ltd.

20070072796 - Oligonucleotide analogues incorporating 5-aza-cytosine therein: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible... Agent: Wilson Sonsini Goodrich & Rosati

20070072802 - Peptide nucleic acid based guanidinium compounds: Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport of a polymer backbone across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The polymer backbone may include peptide nucleic acid monomer units.... Agent: Knobbe Martens Olson & Bear LLP

20070072795 - Treatment of neurodegenerative disorders: A method of treating neurodegenerative disorders of the brain and spinal cord using a novel ethropoietic agent.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072805 - Peptides and their use for the treatment of hiv infections: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is... Agent: Jacobson Holman PLLC

20070072806 - Inhibitor of the folding of the hiv-1-protease as antiviral agent: The invention relates to the design of inhibitors of the HIV-1-PR homodimer which do not create resistance, by blocking the folding of single monomers with the help of peptides which attach to highly-conserved sites of the monomers.... Agent: Shoemaker And Mattare, Ltd

20070072807 - Method of screening compounds: A method of screening compounds to identify those compounds which inhibit the Asp 1 mediated cleavage of a polypeptide or protein substrate, the method comprising: providing a reaction system comprising Asp 1 and substrate; and measuring the extent of cleavage of the substrate in the presence of test compound as... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070072808 - Antimicrobial and anticancer lipopeptides: The invention provides lipophilic conjugates comprising a peptide coupled to a fatty add, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment... Agent: Heslin Rothenberg Farley & Mesiti PC

20070072809 - Antiviral compounds: The invention is related to HCV inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070072810 - Agent for treating diabetes: An agent for treating diabetes with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor. The agent of the present invention is an agent for treating diabetes with sulfonylurea secondary failure showing excellent insulin-secreting and hypoglycemic effects on even diabetic patients on whom a sulfonylurea compound or a fast-acting... Agent: Foley And Lardner LLP Suite 500

20070072811 - Bifunctional heterocyclic compounds and methods of making and using the same: The invention provides a family of bifunctional heterocyclic compounds useful as antiinfective, anti-proliferative, anti-inflammatory, and prokinetic agents. The invention also provides methods of making the bifunctional heterocyclic compounds, and methods of using such compounds as anti-infective, anti-proliferative agents, anti-inflammatory, and/or prokinetic agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070072813 - Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives: The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072812 - Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones: e

20070072814 - Method and means of modulating lipid metabolism: The present invention relates to modulation of lipid metabolism, in particular reductions in the levels of total cholesterol and apo-lipoprotein, of an individual. This modulation is achieved by combined administration of both anti-microbial and metal-chelator compounds. Various therapeutic applications of this lipid modulation are provided.... Agent: Nixon & Vanderhye, PC

20070072819 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070072820 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070072821 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In... Agent: Celera Diagnostics, LLC

20070072815 - Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration: Methods, kits and cell lines are presented for effecting oligonucleotide-directed genetic alteration at a specific locus in a target DNA molecule in a population of cells at increased efficiency.... Agent: Basil S. Krikelis Citizens Bank Center

20070072816 - Methods for inhibiting angiogenesis: Methods for inhibiting angiogenesis using gene therapy are disclosed. Genes encoding PLGF or VEGF-B are delivered to cells e.g., tumor cells, which express VEGF, such that heterodimers of PLGF/VEGF and/or VEGF-B/VEGF are formed within the cells, preferably at a greater ratio than homodimers of VEGF/VEGF. The heterodimers have reduced angiogenic... Agent: Lahive & Cockfield, LLP

20070072817 - Methods for reducing blood pressure: The present invention relates to methods and agents for reducing blood pressure. Methods and agents for reducing diastolic blood pressure, for reducing systolic blood pressure, and for reducing mean arterial pressure are also provided.... Agent: Fibrogen, Inc. Intellectual Property Department

20070072818 - Regulation of angiogenesis with zinc finger proteins: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by... Agent: Townsend And Townsend And Crew, LLP

20070072823 - Sirna targeting survivin: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.... Agent: Kalow & Springut LLP

20070072822 - Stat3 agonists and antagonists and therapeutic uses thereof: The present invention relates to methods for modulating, i.e., agonizing or antagonizing, Stat3 (Signal Transducer and Activator of Transcription3) signaling activity for use in gene therapy. Inhibition and/or activation of Stat3 signaling is an effective approach to modulate angiogenesis and the immune response for treatment and/or prevention of inflammation, infection,... Agent: Fish & Richardson P.C.

20070072826 - Compositions and methods for modulation of vascular structure and/or function: The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as... Agent: Jones Day

20070072824 - Methods of reducing the severity of mucositis: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.... Agent: Clark & Elbing LLP

20070072825 - N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof: The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070072827 - Insecticide formulation: The present invention provides a new insecticide formulation based on cyclodextrin characterised in that the active substance (insecticide and/or insect growth regulator), and a compound synergistic with the active substance, are complexed simultaneously with cyclodextrin. The formulation presents as a solid or as a solid/oil composition, and is soluble or... Agent: Jay S. Cinamon Abelman, Frayne And Schwab

20070072828 - Bile preparations for colorectal disorders: The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or... Agent: Baker Botts L.L.P. Patent Department

20070072829 - Fungicidal composition comprising a pyridylmethylbenzamide derivative and a sulfamide derivative: A composition comprising at least a pyridylmethylbenzamide derivative of general formula (I) and N-dichlorofluoromethylthio-N′,N′-dimethyl-N-p-tolylsulfarnide; in an (a)/(b) weight ratio of from 0.01 to 10. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.... Agent: Ostrolenk Faber Gerb & Soffen

20070072830 - Methods for treating diabetes: The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes.... Agent: Wolf Greenfield & Sacks, PC

20070072831 - Integrase inhibitor compounds: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070072832 - Novel benzopyran derivatives as potassium channel openers: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070072833 - Survivin inhibitors: Compounds that inhibit survivin, compositions containing the compounds and methods of treating diseases in which survivin is unregulated or overexpressed are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070072834 - 13-substituted methacycline compounds: 13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.... Agent: Lahive & Cockfield, LLP

20070072835 - Method of preparing and use of prodrugs of betulinic acid derivatives: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid... Agent: Marshall, Gerstein & Borun LLP

20070072836 - Solid peroral contraceptive preparations: The solid peroral contraceptive contains an effective ingredient combination of dienogest in a daily dosage of equal to or less than 2.0 mg and ethinyl estradiol in a daily dosage of less than 0.03 mg together with one or more pharmaceutically acceptable carriers. The dienogest is released in two stages,... Agent: Striker, Striker & Stenby

20070072837 - Phenylalkynes: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20070072838 - High-purity texaphyrin metal complexes: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further... Agent: Wilson Sonsini Goodrich & Rosati

20070072839 - Leukemia treatment method and composition: A method of inducing high anti-leukemia activity responsive to the combination of hydroxamic acid analogue histone deacetylase inhibitors and PKC412 against human acute leukemia characterized as expressing phosphorylated (p)FLT3 kinase by a novel flow cytometry-based assay.... Agent: Smith Hopen, Pa

20070072840 - Polymorphic forms of quetiapine: The invention relates to processes for the preparation of polymorphic forms of salts of quetiapine. More particularly, it relates to the preparation of polymorphic forms of quetiapine hydrochloride designated as Form A, B, and C. The invention also relates to pharmaceutical compositions that include the Form A, Form B, and... Agent: Ranbaxy Inc.

20070072841 - Therapeutic compounds: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.... Agent: Notaro And Michalos

20070072842 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors: e

20070072843 - Pyridyl substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Proskauer Rose LLP

20070072844 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto: e

20070072845 - Process for the preparation of olanzapine form 1 useful as antipsychotic drug: This invention provides an improved process for the preparation of Olanzapine Form (I). Olanzapine, which is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazapine. More specially, the invention provides insitu improved process for the direct preparation of crystalline form of Olanzapine Form (I). The present invention also provides high pure Olanzapine Form I with single individual impurity... Agent: Moore & Van Allen PLLC

20070072846 - Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto: Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7,T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a... Agent: Leydig, Voit & Mayer, Ltd.

20070072847 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072848 - Combinations of at1-antagonists, amiloride or triamterine, and a diuretic: e

20070072849 - Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods: Non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.... Agent: Fish & Richardson, PC

20070072850 - Pesticides: n

20070072851 - Pyrazolopyridine and pyrazolopyrimidine compounds:

20070072852 - Heterocyclic aspartyl protease inhibitors: and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072853 - Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070072854 - Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive: m

20070072857 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto:

20070072856 - Lpaat-beta inhibitors and uses thereof: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.... Agent: Seed Intellectual Property Law Group PLLC

20070072855 - Pyrazole compounds as hsp90 inhibitors for the treatment of cancer: Compounds of formula (I) are inhibitors of HSP90 activity, and useful in the treatment of proliferative disease such as cancers: wherein R1, R2 and R3 are as defined in the specification, and X is —OR4 or —NR4R5 wherein R4 and R5 independently represent hydrogen or optionally substituted C1-C6 alkyl, or... Agent: Banner & Witcoff

20070072858 - Process for the stereoselective preparation of (-)-halofenate and derivatives thereof: each R2 is a member independently selected from the group consisting of (C1-C4)alkyl, halo, (C1-C4)haloalkyl, amino, (C1-C4)aminoalkyl, amido, (C1-C4)amidoalkyl, (C1-C4)sulfonylalkyl, (C1-C4)sulfamylalkyl, (C1-C4)alkoxy, (C1-C4)heteroalkyl, carboxy and nitro; the subscript n is 1 when R1 has the formula (a) or (b) and 2 when R1 has the formula (c) or (d); the... Agent: Townsend And Townsend And Crew, LLP

20070072859 - Pharmaceutical compounds: The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from —O— and —S—; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each... Agent: Eli Lilly & Company

20070072860 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent: Robert Deberardine Abbott Laboratories

20070072861 - Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.... Agent: Pharmacia Corporation Global Patent Department

20070072862 - Bis-aryl amide compounds and methods of use: wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions... Agent: Amgen Inc.

20070072864 - Fused tricyclic mgiur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072863 - Fused tricyclic mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072865 - Bicyclic piperazine compound and use thereof: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20070072866 - 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase —3β (GSK-3β) which is... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070072867 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5amine: e

20070072868 - Novel synthesis of gatifloxacin: Provided are a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.... Agent: Kenyon & Kenyon LLP

20070072869 - Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders: o

20070072870 - Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition:

20070072871 - Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors: The present invention provides a compound of formula (I):... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070072872 - Treating sexual desire disorders with flibanserin: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072874 - Aminoheteroaryl compounds as protein kinase inhibitors: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.... Agent: Foley And Lardner LLP Suite 500

20070072873 - Novel thiophene derivatives which are hm74a agonists: i

20070072875 - Anti-inflammatory compositions and methods of use: The present invention is directed to pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using these pharmaceutical compositions.... Agent: Brinks Hofer Gilson & Lione

20070072877 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection: The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070072878 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection: The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070072876 - Novel pyrimidine carboxamides: The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the... Agent: Oliff & Berridge, PLC

20070072879 - Novel compounds as metabotropic glutamate receptor antagonists: wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072880 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072881 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072882 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072883 - Fungicidal mixtures:

20070072884 - Quinolin-isoquinolin-and quinazolin-oxyalkylamides and their use as fungicides: in which the optionally substituted phenyl and thienyl rings of the R5 values are optionally substituted with one, two or three substituents selected from halo, hydroxy, mercapto, C1-4 alkyl, C2-4, alkenyl, C2-4 alkynyl, C1-4 alkoxy, C2-4 alkenyloxy, C2-4 alkynyloxy, halo (C1-4)alkyl, halo(C1-4)alkoxy, C1-4 alkylthio, halo(C1-4)alkylthio, hydroxy(C1-4)alkyl, C1-4 alkoxy(C1-4)alkyl, C3-6 cycloalkyl,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070072885 - Bicyclic derivatives for the treatment of abnormal cell growth: and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R5, and X are as defined herein, and wherein the compound of formula 1 optionally further comprises a hydroxy substituent, an O-glucuronic acid, or an N−>O (N-oxide) moiety. The invention also relates to methods of treating abnormal... Agent: Pfizer Inc

20070072886 - Method of treating movement disorders using barbituric acid derivatives: d

20070072888 - Indol-3-yl-carbonyl-azaspiro derivatives: wherein the azaspiro-head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072887 - Spirofuropyridine aryl derivatives: and pharmaceutically-acceptable salts thereof, wherein A, B, and R1 are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070072889 - Hydrocodone polymorphs: Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.... Agent: Philip S. Johnson Johnson & Johnson

20070072890 - Novel crystal forms of irinotecan hydrochloride: The present invention provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating metastatic carcinoma of the colon or rectum using same.... Agent: Cohen, Pontani, Lieberman & Pavane

20070072892 - Amino-aza-adamantane derivatives and methods of use: The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.... Agent: Robert Deberardine Abbott Laboratories

20070072891 - Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts: The instant invention relates to a method for protecting a patient against the risk of cardiac disorders, comprising the administration of a therapeutically effective amount of a tiotropium salt.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072893 - Substituted imidazo ring systems and methods: Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, inter-mediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20070072894 - Synthesis of pyrroloquinoline quinone (pqq): The invention relates to a novel nine step process for synthesizing PQQ (methoxatin). This process is efficient and reliably provides PQQ in excellent purity and high yield.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070072896 - Inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070072897 - Phenylaminopropanol derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072895 - Polymorphs of 1-cyclopropyl-7-([s,s])-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro -8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof: the preparation thereof, and their pharmaceutical compositions are described. These crystalline forms, which are characterized by greater stability and ease of preparation and of formulation, can be produced by industrially applicable methods which comprises the steps of: a) suspending 1-cyclopropyl-7-([S,S])-2,8-diazadicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride in a solvent selected from an alcohol... Agent: Nixon & Vanderhye, PC

20070072899 - Method for treating drug and behavioral addictions: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.... Agent: Robins & Pasternak

20070072898 - Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof: A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.... Agent: Sughrue Mion, PLLC

20070072901 - 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5: p

20070072900 - P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same: The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Sughrue Mion, PLLC

20070072902 - Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses: The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.... Agent: Jones Day

20070072903 - Altering the concentration of intracellular agents by p2x7 receptor modulation: Disclosed is an in vitro method of increasing the effective intracellular concentration of a therapeutic molecule within a cell expressing a P2X7 receptor, the method comprising the step of contacting the cell with the therapeutic molecule and with a substance which stimulates the P2X7 receptor.... Agent: Morgan Lewis & Bockius LLP

20070072904 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds and compounds selective for any one or any two of PPARα, PPARα and PPARδ. Also described are methods of use of the compounds in treating various diseases.... Agent: Foley & Lardner LLP

20070072905 - Novel process for preparing dopenzil and its derivatives: A process for producing a Donepezil derivative represented by the formula (I), wherein R1, R2, R3, and R4 each independently represents H, F, an alkyl having from 1 to 4 carbon atoms, or an alkoxy having from 1 to 4 carbon atoms; R5 represents a phenyl or a substituted phenyl;... Agent: Matthias Scholl

20070072908 - Heterocyclic compounds: p

20070072909 - Methods for making 4-tetrazolyl-4-phenylpiperidine compounds: where Ar1 is —C3-C8 cycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Ar2 is phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Z1 and Z2 are each independently a... Agent: Jones Day

20070072906 - Pyrrole compounds: e

20070072907 - Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070072910 - Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans: The present invention is directed to compositions and method to lower the plasma concentration of a low density lipoprotein in a human. One aspect is the invention is directed to compositions comprising at least one pharmaceutically acceptable L-carnitine compound and at least one pharmaceutically acceptable niacin compound, in such amount... Agent: Knobbe Martens Olson & Bear LLP

20070072911 - Indoles and azaindoles as antiviral agents: The present invention relates to indoles and azaindoles of formula (1): wherein X1, X2, X3, X4, A1, Ar1, Ar, n, p and q are as defined herein and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C virus infections.... Agent: Merck And Co., Inc

20070072912 - Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants: Compounds of the formula (I) and their pharmaceutically acceptable or technically applicable acid salts—where in the formula R1 represents hydrogen, C(1-4)alkyl or C(1-4)alkoxy R2 represents hydrogen, C(1-4)alkyl, carboxyl, C(1-4)alkoxycarbonyl, carboxamido, aryl or hetero-aryl R3 represents hydrogen, C(1-4)alkyl, aryl-methylene, or aryl, Y is a valency bond, a straight or branched chain... Agent: Davis Wright Tremaine LLP

20070072913 - New crystalline form of omeprazole: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation... Agent: White & Case LLP Patent Department

20070072914 - N-(pyridin-2-yl)-sulfonamide derivatives: The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds described herein, their pharmaceutically acceptable salts, hydrates and solvates, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme... Agent: Pfizer Inc

20070072915 - Novel phenoxyacetamide derivative and use thereof for preparation of diphenylamines: The present invention relates to novel phenoxyacetamide derivatives, to a process for the preparation thereof and to the use thereof for the preparation of diphenylamines.... Agent: Millen, White, Zelano & Branigan, P.C.

20070072916 - Amino ceramide-like compounds and therapeutic methods of use: Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070072917 - Substituted 2-aminotetralin for the treatment of depression: The invention relates to the use of a compound of general formula (I) and the pharmaceutically acceptable salts, racemates or pure enantiomers thereof for the production of a medicament used to treat depression. The substituents are defined as in the description.... Agent: Harness, Dickey, & Pierce, P.l.c

20070072918 - Benzothiadiazolylphenylalkylamine derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072920 - Phenylethylamine analogs and their use for treating glaucoma: Phenylethylamine analogs useful for treating glaucoma are disclosed.... Agent: Alcon Research, Ltd. Patrick M. Ryan Tb4-8

20070072919 - Process for the preparation of compounds having an ace inhibitory action: e

20070072921 - Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.... Agent: Pharmacia Corporation Global Patent Department

20070072922 - 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline: An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070072923 - Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde: The present invention provides a process for producing 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde which comprises reacting 2′-cyanobiphenyl-4-carbaldehyde with a salt of azide; a process for producing a highly pure crystal of 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde which comprises reacting 2′-cyanobiphenyl-4-carbaldehyde with a salt of azide, obtaining a crystal of 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde, dissolving said crystal obtained and recrystallizing a highly... Agent: Foley And Lardner LLP Suite 500

20070072924 - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present... Agent: Cozen O'connor, P.C.

20070072925 - Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase: s

20070072926 - 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as... Agent: Allergan, Inc.

20070072927 - Nutritional supplement for increased energy and stamina: In a method of treating hypertension in individuals suffering therefrom, the method includes administering to said individuals an effective amount of carnitine and an effective amount of lipoic acid. A method of treating hypertension in individuals suffering therefrom includes administering twice a day a combination of 500 mg carnitine, 200... Agent: The Luther Law Firm

20070072928 - Substituted propylamine derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072929 - Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines: The present application describes nitroimidazolic derivative compounds with antibacterial and/or antiprotozoal activity, which are potent urease inhibitors. It also describes the process for preparing those compounds and their use in pharmaceutical compositions and medicines.... Agent: Birch Stewart Kolasch & Birch

20070072930 - N-substituted pyrazolyl carboxanilides: e

20070072931 - Pharmaceutical composition and a method for treatment of prostate cancer: The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound... Agent: Brinks Hofer Gilson & Lione

20070072934 - Alkoxy indolinone based protein kinase inhibitors: Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent: The Scripps Research Institute

20070072933 - Delivery of an ocular agent: A method to ameliorate age related macular degeneration or another disease of fluid leakage from new ocular blood vessels to a surrounding area, by administering sunitinib maleate. In one embodiment, sunitinib maleate is administered without photodynamic or laser coagulation therapy. In one embodiment, sunitinib maleate is administered in conjunction with... Agent: Wood, Herron & Evans, LLP

20070072932 - Use of tyrosine kinase inhibitor to treat diabetes: The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1 -ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.... Agent: Novartis Corporate Intellectual Property

20070072935 - Catalytic antioxidants and methods of use: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with... Agent: Akerman Senterfitt

20070072936 - Androgen modulators: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Warner-lambert Company

20070072937 - Pharmaceutical composition comprising alpha-lipoic acid for inflammatory diseases: The present invention relates to a pharmaceutical composition containing α-lipoic acid (LA) as an active ingredient. α-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an... Agent: Birch Stewart Kolasch & Birch

20070072939 - Cannabinoid active pharmaceutical ingredient for improved dosage forms: Pharmaceutical compositions comprising the cannabinoid active pharmaceutical ingredient, crystalline trans-(±)-Δ9-tetrahydrocannabinol, and formulations thereof are disclosed. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of crystalline trans-(±)-Δ9-tetrahydrocannabinol. In specific embodiments, the crystalline trans-(±)-Δ9-tetrahydrocannabinol... Agent: Jones Day

20070072938 - Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting: In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions prior to the administration of chemotherapy to prevent or reduce the development of delayed chemotherapy-induced nausea and vomiting.... Agent: Mayer, Brown, Rowe & Maw LLP

20070072940 - Use of quinol derivatives thereof for cosmetic, dietary supplement or pharmaceutical compositions and compositions thereby obtained.: The present invention relates to a cosmetic, dietary supplement, or pharmaceutical composition for oral ingestion or topical application to the skin comprising effective amounts of a tocopherol quinone, tocopherol quinol, plastoquinol, menaquinol, or phylloquinol compound, or any combination thereof as a method for preventing free radical oxidation or preventing or... Agent: Sal Abraham

20070072941 - Suppression and prevention of tumors: Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in an aqueous liquid such as grape juice and the ingredients are usefully provided in containers with instructions for use, especially with support of tests demonstrating the effectiveness of the... Agent: Robert B. Aylor

20070072942 - Statin derivatives: Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.... Agent: Arent Fox PLLC

20070072943 - Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a... Agent: Morrison & Foerster LLP

20070072944 - Amidoacetonitrile derivatives: The invention relates to compounds of the general formula (I) wherein X, Y and W have the significances given in claim 1 and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites in and on warm-blooded animals.... Agent: Novartis Corporate Intellectual Property

20070072945 - Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake: The present invention relates to sulphur-containing oils, their preparation, and their use in controlling/killing plant pathogens and stimulating a plant's uptake of essential elements from the soil and to act as a soil pH adjuster.... Agent: Ranbaxy Inc.

20070072946 - Milnacipran for the long-term treatment of fibromyalgia syndrome: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with... Agent: Darby & Darby P.C.

20070072947 - Use of deoxypeganine for treating schizophrenic psychoses: Deoxypeganine in the form of a free base or in the form of an acid addition salt, or a derivative of deoxypeganine as long as the derivative is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase. The deoxypeganine can be used for producing a medicament for treating a schizophrenic... Agent: D. Peter Hochberg Co. L.p.a.

20070072948 - Composition comprising long-chain alcohols for suppressing concentrations of c-reactive protein (crp) in human blood: Long-chain alcohols based on montan wax alcohols, beeswax alcohols and Guerbet alcohols can advantageously be used in a composition for efficiently lowering elevated CRP levels. It is surprisingly also possible thereby to influence beneficially pathophysiological processes, in particular CHD, stroke or complications of rheumatoid diseases which are associated with elevated... Agent: Clariant Corporation Intellectual Property Department

20070066512 - Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels: Methods of treating, preventing and/or managing disorders associated with low plasma leptin levels are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.... Agent: Jones Day

20070066513 - Substituted metal-phthalocyanines, their preparation and the use thereof: The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and/or in the diagnosis, as well as for blood and blood derivatives... Agent: Nixon Peabody, LLP

20070066514 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20070066515 - Novel glycoprotein and pharmaceutical composition containing the same: A novel glycoprotein having (a) a molecular weight of approximately 60 kDa and (b) a ratio of a carbohydrate content to a protein content of 16.4:1.0 (carbohydrate: protein) is disclosed. The glycoprotein can be prepared by (1) extracting Tricholoma matsutake with an alkaline solution or hot water, (2) adsorbing the... Agent: Reed Smith LLP

20070066516 - Compounds comprising cyclized somatostatin receptor binding peptides: The present invention concerns compounds comprising novel cyclized peptides with increased selectivity towards binding to the somatostatin receptor 5 (SSTR5) its production and use in the diagnosis and treatment of somatostatin-responsive diseases or diseases characterized by up-regulation of somatostatin receptors, in particular proliferative diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20070066517 - Composition and method for treating graft-versus-host disease: Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute... Agent: Blank Rome LLP

20070066523 - chemokine analogs for the treatment of human diseases: The present invention is concerned with chemokine analogs, including IL-8 analogs, IP-10 analogs, MIP-1α analogs, RANTES analogs, I-309 analogs, MCP-1 analogs, and CCL28 analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and... Agent: Perkins Coie LLP

20070066529 - Acaricidal compositions and methods of use thereof: A method of controlling acarine pests comprises applying to the locus of the acarine pests, an isolated polypeptide toxin, wherein the polypeptide toxin has acaricidal activity. In one embodiment, the polypeptide toxin comprises three intrachain disulfide bonds and/or is a component of a venom of an Australian funnel web spider... Agent: Cantor Colburn, LLP

20070066533 - Cell adhesion inhibitors: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.... Agent: Steptoe & Johnson LLP

20070066532 - Compositions and methods for treatment of muscle pain and muscle wasting: Compositions and methods for alleviating the symptoms associated with muscle pain in general or muscle wasting are provided. The compositions are based on use of androgens, either alone or in combination with other hormones, including growth hormone.... Agent: Licata & Tyrrell P.C.

20070066525 - Compositions and therapeutic methods using morphogenic proteins: The present invention provides pharmaceutical compositions comprising at least two morphogenic proteins, particularly those belonging to the BMP protein family. This invention also provides implantable morphogenic devices comprising a first morphogenic protein and a second morphogenic protein combination disposed within a carrier, that are capable of inducing tissue formation. Methods... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070066527 - Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing alzheimer's disease-like pathology: The present invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070066524 - Mammalian iap gene family, primers, probes and detection methods: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primer and probes for the identification and isolation of additional IAP genes.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070066526 - Method for reducing risk of and extent of injury due to stroke in hypertensive subjects: A method for reducing the risk of stroke in a subject with hypertension is described. The method includes administering an inhibitor of delta protein kinase C (PKC) to the subject. Also described is a method for improving the survival from stroke in a subject with chronic hypertension by treating the... Agent: Perkins Coie LLP

20070066528 - Methods and compositions for treating polycystic ovary syndrome: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070066530 - Methods for modulating gastric secretion using prokineticin receptor antagonists: The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070066531 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070066520 - Novel epidermal growth factor protein and gene, and methods of use therefor: Forms of epidermal growth factor that are resistant to proteolysis, and gene sequences encoding these forms and having codons optimized for usage by an industrial production organism, are provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066518 - Pharmaceutical composition for inducing apoptosis comprising a fusion protein between bfl-1 and green fluorescent protein or a gene encoding same: A pharmaceutical composition comprising a fusion protein between green fluorescent protein and Bfl-1 protein or a gene encoding the fusion protein, as well as a pharmaceutically acceptable carrier, is capable of efficiently inducing apoptosis and useful for treating cancer or cell hyperplasia.... Agent: Sughrue Mion, PLLC

20070066521 - Short rna-binding proteins: The present invention provides compositions, kits, and methods that may be used to bind short RNA molecules, including miRNA and/or siRNA molecules. Such compositions and methods are useful in research and experimental systems to investigate the effects of, for example, miRNAs and/or siRNAs on endogenous and/or exogenous gene expression. Isolated... Agent: Bryan Cave LLP

20070066522 - Tumor inhibition by modulating sprouty expression or activity: Methods are provided for identifying compounds that decrease the expression or activity of an overexpressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is overexpressed. Also provided are therapeutic formulations and pharmaceutical formulations for treating cancers characterized by overexpression of... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070066519 - Use of human growth hormone in multiple system atrophy: The invention relates to the use of a substance, which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance, which stimulates release or potentiates the activity of endogenous hGH, for treatment and/or prevention of Parkinsonism-Plus Syndromes. In particular, the invention relates to the use... Agent: Howrey LLP

20070066535 - Novel haptotactic peptides: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen γ-chain C terminus denoted pre-Cγ possess cell attraction activities, and are useful in pharmaceutical compositions.... Agent: Cooper & Dunham, LLP

20070066534 - Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides... Agent: Fenwick & West LLP

20070066536 - Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators: Methods for treating hormone associated conditions, such as endometriosis, uterine leiomata, ovarian cancer, breast cancer, or vaginal bleeding, using LHRH antagonists and selective estrogen receptor modulators are disclosed. The methods include administering to a subject a combination of an LHRH antagonist and a selective estrogen receptor modulator. Pharmaceutical compositions and... Agent: Lahive & Cockfield, LLP

20070066537 - Compounds and compositions for prevention of overdose of oxycodone: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of... Agent: Hunton & Williams LLP Intellectual Property Department

20070066538 - Treatment of wounds: An isolated protein, for use in treatment of wounds, is characterized in that it is secreted by the organism Lucilia sericata and it exhibits proteolytic activity against FITC-casein at a pH of 8.0 to 8.5. The protein exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC, and its proteolytic activity... Agent: Edwards & Angell, LLP

20070066539 - Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof: The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2-P1 with P1=(A) and P2=(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic... Agent: Clark & Elbing LLP

20070066541 - Compositions and methods for the intraocular transport of therapeutic agents: Membrane transporter-targeted therapeutic agents and methods of making and using the same.... Agent: Stephen Donovan Allergan, Inc.

20070066540 - Growth hormone secretagogue receptor type 1a agonists: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.... Agent: Novo Nordisk, Inc. Patent Department

20070066542 - Novel imidazole derivatives, their preparation and their use as medicaments: m

20070066543 - Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity: The invention provides a method for treating an animal suffering from a disease associated with reduced activity of a lysosomal hexosaminidase by administering to the animal an effective amount of a compound which increases the activity of the hexosaminidase.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070066544 - 3-decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a: their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to intermediates for synthesis of other macrolide compounds with antibacterial activity, to the process for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to the process for the preparation... Agent: Darby & Darby P.C.

20070066545 - Vaginal compositions for treating pelvic tissue infections and traumas: A pharmaceutical composition for use in the treatment and/or prevention of a pelvic tissue infection by vaginal administration comprises an antibiotic and a pharmaceutically acceptable carrier or diluent.... Agent: Ray L Weber Renner Kenner Greive Bobak Taylor & Weber

20070066546 - Compositions for the reversible thioesterification of signaling proteins and methods of using same: Avicins and other thioesterification agents are used to modify cysteine groups of signaling proteins in order to modify their activity. Pathologies associated with signaling proteins which are regulatable through this method are treated using these thioesterification agents. These pathologies include those involving proteins which modulate physiologic redox status of organisms... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066556 - Antisense antiviral compound and method for treating picornavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in